


# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-242) PELABRESIB  
PRONUNCIATION pe lab' re sib  
THERAPEUTIC CLAIM Treatment of myelofibrosis

## CHEMICAL NAMES

1. 4*H*-Isoxazolo[5,4-*d*][2]benzazepine-4-acetamide, 6-(4-chlorophenyl)-1-methyl-, (4*S*)-, hydrate (Source: CAS)
2. (*S*)-2-(6-(4-chlorophenyl)-1-methyl-4*H*-benzo[*c*]isoxazolo[4,5-*e*]azepin-4-yl)acetamide hydrate (Source: ChemDraw)
3. 2-[(4*S*)-6-(4-chlorophenyl)-1-methyl-4*H*- [1,2]oxazolo[5,4-*d*][2]benzazepin-4-yl]acetamide hydrate (Source: WHO pINN list 123)

## STRUCTURAL FORMULA



MOLECULAR FORMULA C<sub>20</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>2</sub>.H<sub>2</sub>O  
MOLECULAR WEIGHT 383.83  
TRADEMARKS None yet  
SPONSOR Constellation Pharmaceuticals, Inc.  
CODE DESIGNATION CPI-0610  
CAS REGISTRY NUMBER 1845726-14-8  
UNII 306QR91I9R  
WHO NUMBER 11382  
SCS